Concert Pharmaceuticals (NASDAQ:CNCE) Rating Lowered to Hold at BidaskClub

Share on StockTwits

Concert Pharmaceuticals (NASDAQ:CNCE) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Friday, BidAskClub reports.

Several other equities analysts have also issued reports on CNCE. UBS Group raised their price objective on L Brands from $26.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, April 10th. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Mizuho reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, May 17th. SunTrust Banks reaffirmed a “buy” rating and set a $35.00 price objective on shares of Whiting Petroleum in a report on Monday, June 24th. Finally, HC Wainwright set a $10.00 price objective on Novavax and gave the stock a “buy” rating in a report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $21.29.

Shares of CNCE stock opened at $11.42 on Friday. The business’s 50-day moving average price is $11.21. The stock has a market capitalization of $268.42 million, a price-to-earnings ratio of -4.76 and a beta of 0.92. Concert Pharmaceuticals has a 1 year low of $9.21 and a 1 year high of $17.86. The company has a debt-to-equity ratio of 0.11, a quick ratio of 20.44 and a current ratio of 20.44.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.31). The firm had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $16.08 million. Concert Pharmaceuticals had a negative return on equity of 41.72% and a negative net margin of 7,118.04%. On average, research analysts forecast that Concert Pharmaceuticals will post -3.78 EPS for the current fiscal year.

In related news, major shareholder Bvf Partners L. P/Il sold 386,289 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $10.70, for a total transaction of $4,133,292.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 9.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Great West Life Assurance Co. Can purchased a new position in shares of Concert Pharmaceuticals during the fourth quarter worth about $48,000. BNP Paribas Arbitrage SA lifted its position in Concert Pharmaceuticals by 63,200.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,431 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 4,424 shares during the period. Metropolitan Life Insurance Co. NY lifted its position in Concert Pharmaceuticals by 452.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,553 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 6,185 shares during the period. Virtu Financial LLC acquired a new stake in Concert Pharmaceuticals in the first quarter valued at about $143,000. Finally, DekaBank Deutsche Girozentrale lifted its position in Concert Pharmaceuticals by 21.6% in the first quarter. DekaBank Deutsche Girozentrale now owns 9,000 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,600 shares during the period. 74.60% of the stock is currently owned by hedge funds and other institutional investors.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

See Also: Options Trading – Understanding Strike Price

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply